Is the genomic translational pipeline being disrupted?

The translational pipeline for genomic medicine has been well defined. However, as with any rapidly changing technology, innovations are difficult to predict leading to the potential to disrupt anticipated translation. Examples of potential disruptors such as laboratory-developed tests, direct-to-consumer testing, and patient-centered research are presented. Awareness of the disruptive nature of innovative approaches is necessary if these innovations are to be incorporated into current practice.

• Publication year

  2015

• Venue

  Human Genomics

• Publication date

  2015-06-14

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1186/s40246-015-0032-4PMID 26070310PMCID 4466858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Revisiting oversight and regulation of molecular-based laboratory-developed tests: a position statement of the Association for Molecular Pathology.

  2014cited by this paper
• Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease

  2014cited by this paper
• Subjects no more: what happens when trial participants realize they hold the power?

  2014cited by this paper
• Implementing genomic medicine in the clinic: the future is here

  2013cited by this paper
• Let the patient revolution begin

  2013cited by this paper
• NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

  2011cited by this paper
• Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm

  2011cited by this paper
• Charting a course for genomic medicine from base pairs to bedside

  2011cited by this paper
• The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

  2007cited by this paper

• Inclusivity in Medical Education: Teaching Integrative and Alternative Medicine in Kentucky

  2021cites this paper
• Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care.

  2020cites this paper
• Where are the breaks in translation from theory to clinical practice (and back) in addressing depression? An empirical graph-theoretic approach

  2018cites this paper
• KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition

  2018cites this paper
• Building a Platform to Enable NCD Research to Address Population Health in Africa: CVD Working Group Discussion at the Sixth H3Africa Consortium Meeting in Zambia.

  2016cites this paper
• The path from big data to precision medicine

  2016cites this paper
• The future of clinical cancer genomics.

  2016cites this paper
• CVD Working Group Discussion at the Sixth H 3 Africa Consortium Meeting in Zambia

  year unknowncites this paper